ArticleGene therapy2004
Adenovirus-based vascular endothelial growth factor gene delivery to human pancreatic islets.
Article in Gene therapy, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 48 citations in OpenAlex.
- β-cell-targeted RNA activation of vascular endothelial growth factor-A improves islet transplantation.Signal transduction and targeted therapy · 2026Article
- Engineering the oxygen microenvironment for pancreatic islet transplants.NPJ Regenerative medicine · 2026Review
- The Influence of Microenvironment on Survival of Intraportal Transplanted Islets.Frontiers in immunology · 2022Review
- Review
- Redox-Dependent Inflammation in Islet Transplantation Rejection.Frontiers in endocrinology · 2018Review
- Vasculogenic hydrogel enhances islet survival, engraftment, and function in leading extrahepatic sites.Science advances · 2017Article
- Engineered VEGF-releasing PEG-MAL hydrogel for pancreatic islet vascularization.Drug delivery and translational research · 2015Article
- PEG-maleimide hydrogels for protein and cell delivery in regenerative medicine.Annals of biomedical engineering · 2014Article
- Vasculogenic bio-synthetic hydrogel for enhancement of pancreatic islet engraftment and function in type 1 diabetes.Biomaterials · 2013Article
- RGD peptide-modified adenovirus expressing hepatocyte growth factor and X-linked inhibitor of apoptosis improves islet transplantation.The journal of gene medicine · 2011Article
- Genetically modified mesenchymal stem cells for improved islet transplantation.Molecular pharmaceutics · 2011Review
- Article
- Silencing of the IKKε gene by siRNA inhibits invasiveness and growth of breast cancer cells.Breast cancer research : BCR · 2010Article
- Gene expression and silencing for improved islet transplantation.Journal of controlled release : official journal of the Controlled Release Society · 2009Review
- Reverse genetics technology for Rift Valley fever virus: current and future applications for the development of therapeutics and vaccines.Antiviral research · 2009Review
- Transfection of rat pancreatic islet tissue by polymeric gene vectors.Diabetes technology & therapeutics · 2009Article
- Bipartite adenoviral vector encoding hHGF and hIL-1Ra for improved human islet transplantation.Pharmaceutical research · 2009Article
- Co-expression of vascular endothelial growth factor and interleukin-1 receptor antagonist improves human islet survival and function.Pharmaceutical research · 2006Article
- Ischaemia is linked to inflammation and induction of angiogenesis in pancreatic islets.Clinical and experimental immunology · 2006Review
- Bipartite vector encoding hVEGF and hIL-1Ra for ex vivo transduction into human islets.Molecular pharmaceuticsArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
Abstract
Islet transplantation is limited by islet graft failure due to poor revascularization, host immune rejection and nonspecific inflammatory response. Delivery of human vascular endothelial growth factor (hVEGF) gene to the islets is likely to promote islet revascularization and survival. We used a bicistronic adenoviral vector encoding hVEGF and CpG-free allele of green fluorescent protein (Adv-GFP-hVEGF) and introduced into human pancreatic islets by transfection. We found that transfection efficiency and apoptosis were dependent on the multiplicity of infection (MOI). Compared to Adv-GFP transfected and nontransfected islets, the levels of hVEGF secreted from Adv-GFP-hVEGF transfected islets were higher and exhibit a linear relationship between hVEGF expression and MOI (10-5000). Persistent, but low level expression of hVEGF from nontransfected islets was also observed. This may be due to expression of the endogenous hVEGF gene under hypoxic conditions. The levels of DNA fragmentation determined by ELISA of islet lysates were dependent on the MOI of Adv-GFP-hVEGF. On glucose challenge, insulin release from transfected islets was comparable to nontransfected islets. Immunohistochemical staining for hVEGF was very high in Adv-GFP-hVEGF transfected islets. Weak staining was also observed for hCD31 in both transfected and nontransfected islets. These findings suggest that Adv-GFP-hVEGF is a potential candidate for promoting islet revascularization.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.